PHA-767491

CAT: 0804-HY-13461-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13461-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
CAS Number
[845714-00-3]
Product Name Alternative
CAY10572
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pha-767491.html
Purity
99.97
Solubility
DMSO : 15.38 mg/mL (ultrasonic; adjust pH to 2 with 1 M HCL)
Smiles
O=C1C2=C(NC(C3=CC=NC=C3)=C2)CCN1
Molecular Formula
C12H11N3O
Molecular Weight
213.24
Precautions
H315, H319, H320
References & Citations
[1]Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9 (11) :e113300.|[2]Li W, et al. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15 (3) :196-204.|[3]Erbayraktar Z, et al. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88.|[4]Montagnoli A, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4 (6) :357-65.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK5; CDK9
Citation 01
Acta Pharmacol Sin. 2022 Apr;43 (4) :1033-1045.|Nat Commun. 2024 Dec 5;15 (1) :10594.|Autophagy. 2022 Aug;18 (8) :1879-1897.|Sci Rep. 2021 Mar 8;11 (1) :5374.

Popular Products